A drug against melanoma being described by researchers as “phenomenal” is one step closer to being widely available to patients after results of an early study were released two days ago. The gene therapy drug acts against the BRAF protein that causes skin cells to abnormally replicate. Dr Keith Flaherty of the Developmental Therapeutics Institute at Massachusetts General Hospital and Dr. Lynn Schuchter at the University of Pennsylvania took part in the study and comment.
Leave a Reply